BIOTEC, Novartis Extend Partnership To Mine Thai Biodiversity For Drug Discovery
This article was originally published in PharmAsia News
Executive Summary
Novartis exchanges training for access to Thailand’s native natural compounds for drug discovery.
You may also be interested in...
Novartis Head of Corporate Research And Chairman, Novartis Institute For Tropical Diseases, Paul Herrling On The Need For Government Funding For Neglected Diseases: An Interview With PharmAsia News
Paul Herrling, Head of Corporate Research at Novartis and Chairman of the Novartis Institute For Tropical Diseases, Singapore spends a week each month in Singapore and for the rest he fulfills his other global commitments. Herrling sat down with PharmAsia News in Singapore to discuss research initiatives for neglected diseases and controversies revolving around his proposal for a fund to research neglected diseases by multiple governments.
Big Pharma More Willing To Cooperate On Neglected Disease Research But Funding Models Still Unclear
HONG KONG - Debate over how best to fund research and development of neglected diseases may be reshaped by changing patterns of cooperation among Big Pharma and non-industry groups
Sanofi Asks Thailand To Review Compulsory Licensing Policy
Sanofi-Aventis sent a request to the previous Thai Minister of Commerce Mingkwan Sangsuwan to review the process of compulsory licensing on patented drugs, Graham Almond, Sanofi-Aventis Thailand general manager told PharmAsia News.